EMT2
Omega-3 polyunsaturated fatty acid eicosapentaenoic acid (EPA) versus placebo after resection of colorectal cancer liver metastases (EMT2): A multicentre, double-blind, randomised phase 3 trial
In patients undergoing resection of colorectal cancer liver metastases, eicosapentaenoic acid did not improve progression-free survival compared with placebo, although overall survival, a secondary endpoint, was nominally improved.
This double-blind, placebo-controlled trial shows that EPA did not improve its primary endpoint, progression-free survival. The overall survival gain is a key secondary endpoint, and the abstract describes no hierarchical testing, so its P value is nominal and the finding is hypothesis-generating. The abstract does not report median follow-up, the number of deaths, or treatment after progression, and it does not explain how survival could improve without any effect on progression. The confidence intervals around five-year survival are wide, and safety is summarised only in qualitative terms.